Rajangam Kanya has filed 14 insider transactions across 2 companies since February 2023.
Most recent transaction: a tax payment of 10757 shares of Senti Biosciences, Inc. ($SNTI) on March 09, 2026.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | F | Common Stock | 10757 | $0.00 | 74,843.0000 | 26,290,838 | 12.57% | 0.04% |
| Feb. 2, 2026 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | F | Common Stock | 1384 | $0.00 | 85,600.0000 | 26,290,838 | 1.59% | 0.01% |
| March 10, 2025 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | C | Common Stock | 33000 | $2.25 | 119,984.0000 | 4,829,035 | 37.94% | 0.68% |
| March 10, 2025 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | C | Series A Convertible Preferred Stock | 33 | $2250.00 | 0.0000 | 4,829,035 | 100.00% | 0.00% |
| March 6, 2025 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | A | Stock Option (Right to Buy) | 235088 | $0.00 | 235,088.0000 | 4,829,035 | 9999.99% | 4.87% |
| March 7, 2025 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | A | Common Stock | 78363 | $0.00 | 86,984.0000 | 4,829,035 | 908.98% | 1.62% |
| Feb. 4, 2025 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | S | Common Stock | 1297 | $4.07 | 8,803.0000 | 4,829,035 | 12.84% | 0.03% |
| Feb. 6, 2025 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | S | Common Stock | 182 | $4.37 | 8,621.0000 | 4,829,035 | 2.07% | 0.00% |
| Dec. 9, 2024 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | A | Series A Convertible Preferred Stock | 33 | $2250.00 | 33.0000 | 4,586,957 | 9999.99% | 0.00% |
| Dec. 9, 2024 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | A | Common Stock Warrant (right to buy) | 49500 | $0.00 | 49,500.0000 | 4,586,957 | 9999.99% | 1.08% |
| June 3, 2024 | Turnstone Biologics Corp. | $TSBX | Rajangam Kanya | Not found | A | Stock Option (Right to Buy) | 12770 | $0.00 | 12,770.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Chief Medical & Devt. Officer | A | Stock Option (Right to Buy) | 152000 | $0.00 | 152,000.0000 | 4,569,900 | 9999.99% | 3.33% |
| Feb. 1, 2024 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Chief Medical & Devt. Officer | A | Common Stock | 101000 | $0.00 | 101,000.0000 | 4,569,900 | 9999.99% | 2.21% |
| Feb. 1, 2023 | Senti Biosciences, Inc. | $SNTI | Rajangam Kanya | Chief Medical & Devt. Officer | A | Stock Option (Right to Buy) | 130000 | $0.00 | 130,000.0000 | 4,406,137 | 9999.99% | 2.95% |